Home » Teva Multiple-Sclerosis Treatment Meets Goals in New Dosing Regimen
Teva Multiple-Sclerosis Treatment Meets Goals in New Dosing Regimen
Teva Pharmaceutical Industries said its multiple-sclerosis treatment administered three times a week reduced the annual relapse rate by more than 34 percent compared with a placebo in a one-year clinical trial.
Fox Business
Fox Business
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May